1. Home
  2. CING

as of 09-09-2026 4:00pm EST

$5.21
+$0.02
+0.39%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Founded: 2012 Country:
United States
United States
Employees: N/A City: KANSAS CITY
Market Cap: 64.5M IPO Year: 2021
Target Price: $34.50 AVG Volume (30 days): 133.6K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.32 EPS Growth: 56.47
52 Week Low/High: $3.16 - $11.89 Next Earning Date: 05-08-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -3.93 Index: N/A
Free Cash Flow: -17407320.0 FCF Growth: N/A

AI-Powered CING Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 75.61%
75.61%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 13, 2026 · 100% conf.

AI Prediction SELL

1D

-8.96%

$4.54

Act: +2.00%

5D

-18.08%

$4.09

20D

-14.51%

$4.27

Price: $4.99 Prob +5D: 0% AUC: 1.000
0001493152-26-037605

Transcript text not available. View on SEC.gov →

2026
Q1

Q1 2026 Earnings

8-K

May 14, 2026

0001493152-26-022881

Transcript text not available. View on SEC.gov →

2025
Q4

Q4 2025 Earnings

8-K

Mar 18, 2026

0001493152-26-010881

Transcript text not available. View on SEC.gov →

Share on Social Networks: